Nick DeVito
@ndevitomd.bsky.social
Assistant Prof, GI Oncologist @
Duke Cancer researching immunotherapy, metastasis, and the immune microenvironment.
#FirstGen. USouthFlorida alumnus. Tufts residency survivor.
Patients don’t fail treatments, treatments fail patients.
Opinions=mine
Duke Cancer researching immunotherapy, metastasis, and the immune microenvironment.
#FirstGen. USouthFlorida alumnus. Tufts residency survivor.
Patients don’t fail treatments, treatments fail patients.
Opinions=mine
Pinned
Nick DeVito
@ndevitomd.bsky.social
· Feb 24
Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling - PubMed
Therapeutic resistance to immune checkpoint blockade has been commonly linked to the process of mesenchymal transformation (MT) and remains a prevalent obstacle across many cancer types. An improved m...
pubmed.ncbi.nlm.nih.gov
After about 7 years of work and 9 months in review, our manuscript is finally PUBLISHED in Cancer Research!!!!
Here we describe tumor immune evasion during mesenchymal plasticity induced by the hedgehog transcription factor Gli2– time for a...bluetorial? skytorial?
pubmed.ncbi.nlm.nih.gov/39970333/
Here we describe tumor immune evasion during mesenchymal plasticity induced by the hedgehog transcription factor Gli2– time for a...bluetorial? skytorial?
pubmed.ncbi.nlm.nih.gov/39970333/
My overview of MSI-H colorectal cancer management post ASCO and ESMO, aka “the ATOMIC diss track,” is up on VuMedi:
www.vumedi.com/video/manage...
www.vumedi.com/video/manage...
Management of MSI-H CRC Including New Data From ESMO 2025
A video from Nicholas Devito (as part of Duke Cancer Institute), posted on Oct 31, 2025.
www.vumedi.com
November 10, 2025 at 9:59 PM
My overview of MSI-H colorectal cancer management post ASCO and ESMO, aka “the ATOMIC diss track,” is up on VuMedi:
www.vumedi.com/video/manage...
www.vumedi.com/video/manage...
Reposted by Nick DeVito
Next week LinkedIn will use your personal data for AI training by automatically enabling permissions.
To manually turn off go to:
Settings ➡️ Data Privacy ➡️ under
“How LinkedIn uses your data” click “Data for Generative AI improvement” ➡️ toggle off
To manually turn off go to:
Settings ➡️ Data Privacy ➡️ under
“How LinkedIn uses your data” click “Data for Generative AI improvement” ➡️ toggle off
November 2, 2025 at 5:07 AM
Next week LinkedIn will use your personal data for AI training by automatically enabling permissions.
To manually turn off go to:
Settings ➡️ Data Privacy ➡️ under
“How LinkedIn uses your data” click “Data for Generative AI improvement” ➡️ toggle off
To manually turn off go to:
Settings ➡️ Data Privacy ➡️ under
“How LinkedIn uses your data” click “Data for Generative AI improvement” ➡️ toggle off
Reposted by Nick DeVito
Join us as we take a step back in time and celebrate all we have accomplished in immuno-oncology over the past 40 years! We will be remembering all our IO milestones as we lead up to our 40th Anniversary Annual Meeting! sitcancer.org/2025/home
September 29, 2025 at 1:38 PM
Join us as we take a step back in time and celebrate all we have accomplished in immuno-oncology over the past 40 years! We will be remembering all our IO milestones as we lead up to our 40th Anniversary Annual Meeting! sitcancer.org/2025/home
Extremely useful for spectral flow cytometry enthusiasts- thanks @labliston.bsky.social I will share with our core too
Pre-print alert! And this one really is a must read for anyone that does spectral #flowcytometry. It is a complete, fully-automated spectral unmixing pipeline that reduces error up to 9000-fold.
Want to get a tough sample, like lung, looking like this? Read more!
www.biorxiv.org/content/10.1...
Want to get a tough sample, like lung, looking like this? Read more!
www.biorxiv.org/content/10.1...
October 28, 2025 at 3:22 PM
Extremely useful for spectral flow cytometry enthusiasts- thanks @labliston.bsky.social I will share with our core too
Reposted by Nick DeVito
Finally read the paper and it's worth the buzz.
mRNA vaccines saved 20 million lives in a global pandemic and the technology is opening up new avenues for the treatment of deadly cancers. This is really one of the most impactful scientific developments of our time.
www.nature.com/articles/s41...
mRNA vaccines saved 20 million lives in a global pandemic and the technology is opening up new avenues for the treatment of deadly cancers. This is really one of the most impactful scientific developments of our time.
www.nature.com/articles/s41...
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade - Nature
mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
www.nature.com
October 25, 2025 at 1:42 PM
Finally read the paper and it's worth the buzz.
mRNA vaccines saved 20 million lives in a global pandemic and the technology is opening up new avenues for the treatment of deadly cancers. This is really one of the most impactful scientific developments of our time.
www.nature.com/articles/s41...
mRNA vaccines saved 20 million lives in a global pandemic and the technology is opening up new avenues for the treatment of deadly cancers. This is really one of the most impactful scientific developments of our time.
www.nature.com/articles/s41...
YAP is a tough drug target with implications in resistance to immunotherapy and other treatments, these are some very encouraging results
www.nature.com/articles/s41...
www.nature.com/articles/s41...
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial - Nature Medicine
As presented at the European Society for Medical Oncology Congress 2025: In patients with locally advanced or metastatic solid tumours, including mesothelioma, treatment with a first-in-class inhibito...
www.nature.com
October 20, 2025 at 2:09 PM
YAP is a tough drug target with implications in resistance to immunotherapy and other treatments, these are some very encouraging results
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The tumor immunology and immunotherapy lecture "Know the System Know the Drug,” that Dan Schrum and I recorded for trainees, is up on YouTube!
If you are interested in tumor immune evasion and immunotherapeutic mechanisms of action, check out our talk.
m.youtube.com/watch?v=atiS...
If you are interested in tumor immune evasion and immunotherapeutic mechanisms of action, check out our talk.
m.youtube.com/watch?v=atiS...
Immunology for Oncology Fellows Faculty and Pharmacy Residents
YouTube video by DukeCancerInstitute
m.youtube.com
October 18, 2025 at 9:58 AM
The tumor immunology and immunotherapy lecture "Know the System Know the Drug,” that Dan Schrum and I recorded for trainees, is up on YouTube!
If you are interested in tumor immune evasion and immunotherapeutic mechanisms of action, check out our talk.
m.youtube.com/watch?v=atiS...
If you are interested in tumor immune evasion and immunotherapeutic mechanisms of action, check out our talk.
m.youtube.com/watch?v=atiS...
Reposted by Nick DeVito
No words
May 30, 2025 at 12:23 PM
No words
Reposted by Nick DeVito
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression https://www.medrxiv.org/content/10.1101/2025.10.06.25337175v1
October 7, 2025 at 10:28 PM
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression https://www.medrxiv.org/content/10.1101/2025.10.06.25337175v1
Lactate impairs TLS formation - nice pre print www.biorxiv.org/content/10.1...
Lactate Blocks Tertiary Lymphoid Structure Formation by Inhibiting B Cell Chemotaxis
Tertiary lymphoid structures (TLS) and B cell infiltration are strong predictors of immunotherapy success across cancers, including triple-negative breast cancer (TNBC). However, immune-cold TNBCs oft...
www.biorxiv.org
October 7, 2025 at 4:39 PM
Lactate impairs TLS formation - nice pre print www.biorxiv.org/content/10.1...
Reposted by Nick DeVito
A small primer on the #NobelPrize awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi today. This prize was for combining two separate fields of immunology research - genetic research on IPEX and immunology research of regulatory T cells (#Tregs), with enormous impact on biology/medicine
October 6, 2025 at 11:21 AM
A small primer on the #NobelPrize awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi today. This prize was for combining two separate fields of immunology research - genetic research on IPEX and immunology research of regulatory T cells (#Tregs), with enormous impact on biology/medicine
“Chris wasn’t even 10 and government funding was already working toward his cure. So, what are we risking in 30 years by cutting NIH funding?
…that progress gave us the tools we needed to treat Chris the right way, up front, with the standard of care, since the science and trials had been done.”
…that progress gave us the tools we needed to treat Chris the right way, up front, with the standard of care, since the science and trials had been done.”
One of my amazing patients who is in remission from MSI-H colorectal cancer after immunotherapy is featured!! I am so proud 🥹
Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
October 5, 2025 at 12:54 PM
“Chris wasn’t even 10 and government funding was already working toward his cure. So, what are we risking in 30 years by cutting NIH funding?
…that progress gave us the tools we needed to treat Chris the right way, up front, with the standard of care, since the science and trials had been done.”
…that progress gave us the tools we needed to treat Chris the right way, up front, with the standard of care, since the science and trials had been done.”
Reposted by Nick DeVito
One of my amazing patients who is in remission from MSI-H colorectal cancer after immunotherapy is featured!! I am so proud 🥹
Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Former NCI official’s nonprofit seeks to tell the stories of cancer patients Patient Action for Cancer Research aims to show impact of federal research - The Cancer Letter
Chris Biggar, a 34-year-old from Ohio, had just landed his dream job working in R&D when he was diagnosed with stage 4 colon cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]
cancerletter.com
October 3, 2025 at 11:54 PM
One of my amazing patients who is in remission from MSI-H colorectal cancer after immunotherapy is featured!! I am so proud 🥹
Reposted by Nick DeVito
It’s the difference between life & death.
The wellness industry profits by creating distrust of medicine, falsely claiming “real” cancer cures are being hidden so doctors can keep patients sick & poison them with chemotherapy.
They are lying to you. With fatal consequences. While making money.
3/
The wellness industry profits by creating distrust of medicine, falsely claiming “real” cancer cures are being hidden so doctors can keep patients sick & poison them with chemotherapy.
They are lying to you. With fatal consequences. While making money.
3/
October 5, 2025 at 12:15 AM
It’s the difference between life & death.
The wellness industry profits by creating distrust of medicine, falsely claiming “real” cancer cures are being hidden so doctors can keep patients sick & poison them with chemotherapy.
They are lying to you. With fatal consequences. While making money.
3/
The wellness industry profits by creating distrust of medicine, falsely claiming “real” cancer cures are being hidden so doctors can keep patients sick & poison them with chemotherapy.
They are lying to you. With fatal consequences. While making money.
3/
One of my amazing patients who is in remission from MSI-H colorectal cancer after immunotherapy is featured!! I am so proud 🥹
Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Former NCI official’s nonprofit seeks to tell the stories of cancer patients Patient Action for Cancer Research aims to show impact of federal research - The Cancer Letter
Chris Biggar, a 34-year-old from Ohio, had just landed his dream job working in R&D when he was diagnosed with stage 4 colon cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]
cancerletter.com
October 3, 2025 at 11:54 PM
One of my amazing patients who is in remission from MSI-H colorectal cancer after immunotherapy is featured!! I am so proud 🥹
Reposted by Nick DeVito
Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Former NCI official’s nonprofit seeks to tell the stories of cancer patients Patient Action for Cancer Research aims to show impact of federal research - The Cancer Letter
Chris Biggar, a 34-year-old from Ohio, had just landed his dream job working in R&D when he was diagnosed with stage 4 colon cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]
cancerletter.com
October 3, 2025 at 9:05 PM
Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Patient Action for Cancer Research aims to show impact of federal research
https://cancerletter.com/the-cancer-letter/20251003_1/
Reposted by Nick DeVito
Early-onset gastrointestinal cancer is currently the most rapidly increasing early-onset cancer in the US.
This JAMA Patient Page describes early-onset GI cancer and its risk factors, signs and symptoms, management, prognosis, and prevention measures.
ja.ma/46BERoo
This JAMA Patient Page describes early-onset GI cancer and its risk factors, signs and symptoms, management, prognosis, and prevention measures.
ja.ma/46BERoo
October 3, 2025 at 11:00 AM
Early-onset gastrointestinal cancer is currently the most rapidly increasing early-onset cancer in the US.
This JAMA Patient Page describes early-onset GI cancer and its risk factors, signs and symptoms, management, prognosis, and prevention measures.
ja.ma/46BERoo
This JAMA Patient Page describes early-onset GI cancer and its risk factors, signs and symptoms, management, prognosis, and prevention measures.
ja.ma/46BERoo
Reposted by Nick DeVito
The Damage Done: @marianneguenot.bsky.social tells the story of clinical trials derailed by the administration's reckless science policy, across kidney disease, HIV, Alzheimer's disease, and cancer. Years of work and money thrown away, at times just short of a cure.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The damage done - Nature Medicine
When clinical trials are suddenly halted by US funding cuts, there are repercussions for investigators and patients, and they do not stop at borders.
www.nature.com
September 30, 2025 at 10:27 PM
The Damage Done: @marianneguenot.bsky.social tells the story of clinical trials derailed by the administration's reckless science policy, across kidney disease, HIV, Alzheimer's disease, and cancer. Years of work and money thrown away, at times just short of a cure.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Nick DeVito
Out now in #Science #Immunology: Zhenghai Tang (U of Macau) & André Veillette (@ircm.bsky.social / @mcgill.ca / @umontreal.ca) review the latest research on inhibitory #ImmuneCheckpoints in #cancer #immunotherapy. Check it out!
Inhibitory immune checkpoints in cancer immunotherapy
Inhibitory immune checkpoints for cancer immunotherapy are reviewed.
www.science.org
September 29, 2025 at 8:50 PM
Out now in #Science #Immunology: Zhenghai Tang (U of Macau) & André Veillette (@ircm.bsky.social / @mcgill.ca / @umontreal.ca) review the latest research on inhibitory #ImmuneCheckpoints in #cancer #immunotherapy. Check it out!
Reposted by Nick DeVito
ICYMI: New online! Food as medicine in gastrointestinal cancer therapy
Food as medicine in gastrointestinal cancer therapy
Nature Reviews Gastroenterology & Hepatology, Published online: 18 September 2025; doi:10.1038/s41575-025-01117-0Diet modulates not only gastrointestinal cancer risk but also survivorship, providing an opportunity to improve cancer-related outcomes and quality of life through suitable dietary and lifestyle interventions in survivors of cancer. This Comment summarizes the evidence and ongoing trials investigating diet in gastrointestinal cancer survival, including potential underlying mechanisms and future research directions.
www.nature.com
September 24, 2025 at 3:28 PM
ICYMI: New online! Food as medicine in gastrointestinal cancer therapy
Reposted by Nick DeVito
Early-onset colorectal cancer is expected to become the leading cause of #cancer death in ages 20 to 49 in the U.S. by 2030.
Research is urgently needed to better detect and treat patients, argues this #SciencePerspective: https://scim.ag/3IfUgBA #WorldCancerResearchDay
Research is urgently needed to better detect and treat patients, argues this #SciencePerspective: https://scim.ag/3IfUgBA #WorldCancerResearchDay
A common cancer at an uncommon age
The etiology of early-onset colorectal cancer needs to be understood to tackle rising incidence
scim.ag
September 24, 2025 at 1:15 PM
Early-onset colorectal cancer is expected to become the leading cause of #cancer death in ages 20 to 49 in the U.S. by 2030.
Research is urgently needed to better detect and treat patients, argues this #SciencePerspective: https://scim.ag/3IfUgBA #WorldCancerResearchDay
Research is urgently needed to better detect and treat patients, argues this #SciencePerspective: https://scim.ag/3IfUgBA #WorldCancerResearchDay
Reposted by Nick DeVito
🧪🧪 Just a reminder, a 2024 study published in JAMA that included over 2 million children found that using acetaminophen, the active ingredient in Tylenol, during pregnancy was not associated with increased risk of autism, ADHD, or intellectual disability in children.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability
This nationwide cohort study with sibling control analysis examines the association of acetaminophen use during pregnancy with children’s risk of autism, ADHD, and intellectual disability.
jamanetwork.com
September 22, 2025 at 2:55 PM
🧪🧪 Just a reminder, a 2024 study published in JAMA that included over 2 million children found that using acetaminophen, the active ingredient in Tylenol, during pregnancy was not associated with increased risk of autism, ADHD, or intellectual disability in children.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Nick DeVito
Reading papers is a basic skill (and dare I say duty?) of scientists, and I include medical doctors in that group. Keeping abreast of the literature is a foundational part of our professions. There aren’t good shortcuts. In any case, reading papers regularly is fun.
arstechnica.com/ai/2025/09/s...
arstechnica.com/ai/2025/09/s...
Science journalists find ChatGPT is bad at summarizing scientific papers
LLM “tended to sacrifice accuracy for simplicity” when writing news briefs.
arstechnica.com
September 21, 2025 at 6:22 AM
Reading papers is a basic skill (and dare I say duty?) of scientists, and I include medical doctors in that group. Keeping abreast of the literature is a foundational part of our professions. There aren’t good shortcuts. In any case, reading papers regularly is fun.
arstechnica.com/ai/2025/09/s...
arstechnica.com/ai/2025/09/s...